{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T11:26:50Z","timestamp":1696591610055},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2012,4,1]]},"DOI":"10.2174\/156800912800190965","type":"journal-article","created":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T16:48:37Z","timestamp":1334594917000},"page":"391-401","source":"Crossref","is-referenced-by-count":3,"title":["Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients"],"prefix":"10.2174","volume":"12","author":[{"given":"M.","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/96711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T10:11:19Z","timestamp":1448273479000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1568-0096&volume=12&issue=4&spage=391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/156800912800190965","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4,1]]}}}